Myocardial hypertrophy in infants in pediatric practice
- Authors: Basargina EN1, Ermolenko VS1, Sil’nova IV1
-
Affiliations:
- Scientific Centre of Children Health, Moscow, Russia
- Issue: Vol 96, No 4 (2015)
- Pages: 647-653
- Section: IX Russian Seminar dedicated to the memory of Prof. N.A. Belokon’
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/2267
- DOI: https://doi.org/10.17750/KMJ2015-647
- ID: 2267
Cite item
Full Text
Abstract
Aim. To identify the features of the diseases associated with myocardial hypertrophy, for an earlier differential diagnosis to determine the treatment tactics and to initiate the early treatment.
Methods. Clinical examination, family history, cardiac ultrasound with Doppler, ECG, 24-hour ECG monitoring, and computed tomographic aortography and genetics counseling (if indicated) were preformed.
Results. During 14 years of observations, 92 patients were included, among them: children with idiopathic hypertrophic cardiomyopathy - 49 (53%), followed by children with Noonan syndrome - 11 (11.9%), Pompe disease - 6 (6.5%), hypertension - 6 (6.5%), Leopard syndrome - 5 (5,4%), Friedrich ataxia - 4 (4.3%), Danon disease - 3 (3.2%), cardiofaciocutaneous syndrome, fatty acids beta-oxidation disorder and mucopolysaccharidosis type I (Hurler syndrome) - 2 (2.1%), carnitine deficiency and GM1-gangliosidosis - 1 (1.2%).
Conclusion. Consudering the possibilities of modern medicine, diagnosis of left and/or right ventricular hypertrophy in pediatric general practice and pediatric cardiology is an important factor for the subsequent diagnostic search, earliest possible specific therapeutic interventions to prevent unfavorable outcomes of the diseases.
About the authors
E N Basargina
Scientific Centre of Children Health, Moscow, Russia
Author for correspondence.
Email: basargina@nczd.ru
V S Ermolenko
Scientific Centre of Children Health, Moscow, Russia
Email: basargina@nczd.ru
I V Sil’nova
Scientific Centre of Children Health, Moscow, Russia
Email: basargina@nczd.ru
References
- Arad M., Seidman C.E., Seidman J.G. AMP-activated protein kinase in the heart: role during health and disease // Circ. Res. - 2007. - Vol. 100, N 4. - P. 474-488. http://dx.doi.org/10.1161/01.RES.0000258446.23525.37
- Bernard J.G., Barry J.M., Robert O.B. et al. Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy // Circulation. - 2011. - Vol. 124. - Р. e783-e831. http://dx.doi.org/10.1161/CIR.0b013e318223e2bd
- Digilio M.C., Conti E., Sarkozy A. et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 Gene // Am. J. Hum. Genet. - 2002. - Vol. 71. - P. 389-394. http://dx.doi.org/10.1086/341528
- Digilio M.C., Sarkozy A., de Zorzi A. et al. LEOPARD syndrome: clinical diagnosis in the first year of life // Am. J. Med. Genet. A. - 2006. - Vol. 140A. - P. 740-674. http://dx.doi.org/10.1002/ajmg.a.31156
- Fanin M., Nascimbeni A.C., Fulizio L. et al. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease // Am. J. Pathol. - 2006. - Vol. 168, N 4. - P. 1309-1320. http://dx.doi.org/10.2353/ajpath.2006.050646
- Frank W.N., Dan L., Kai H. et al. The cardiomyopathy in Friedreich’s ataxia - new biomarker for staging cardiac involvement // Intern. J. Cardiol. - 2015. - Vol. 194. - P. 50-57. http://dx.doi.org/10.1016/j.ijcard.2015.05.074
- James D.W., Sleeper L.A., Alvarez J.A. et al. The pediatric cardiomyopathy registry: 1995-2007 // Prog. Pediatr. Cardiol. - 2008. - Vol. 25, N 1. - P. 31-36. http://dx.doi.org/10.1016/j.ppedcard.2007.11.006
- Maron B.J., McKenna W.J., Danielson G.K. et al. American Collage of Cardiology / European Society of Cardiology clinical expert consensus document of hypertrophic cardiomyopathy. A report of American Collage of Cardiology Foundation Task Force on Clinical Expert consensus Documents and the European Society of Cardiology Committee for Practice Guidelines // Eur. J. Am. Coll. Cardiol. - 2003. - Vol. 42, N 9. - P. 1687-1713. http://dx.doi.org/10.1016/S0735-1097(03)00941-0
- Maron B.J., Seidman C.E., Ackerman M.J. et al. How should hypertrophic cardiomyopathy be classified? What’s in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy // Circ. Cardiovasc. Genet. - 2009. - Vol. 2, N 1. - P. 81-85. http://dx.doi.org/10.1161/CIRCGENETICS.108.788703
- Martina B., Volker S., Arnold J.J. Pompe disease. 1st edition. - UNI-MED Science, 2008. - 84 p.
- Roberts A., Allanson J., Jadico S.K. et al. The cardiofaciocutaneous syndrome // J. Med. Genet. - 2006. - Vol. 43. - P. 833-842. http://dx.doi.org/10.1136/jmg.2006.042796
- Sarkozy A., Carta C., Moretti S. et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum // Hum. Mutat. - 2009. - Vol. 30. - P. 695-702. http://dx.doi.org/10.1002/humu.20955
- Seward J.B., Casaclang-Verzosa G. Infiltrative cardiovascular diseases // J. Am. Coll. Cardiol. - 2010. - Vol. 55. - P. 1769-1779. http://dx.doi.org/10.1016/j.jacc.2009.12.040
- Sznajer Y., Keren B., Baumann C. et al. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene // Pediatrics. - 2007. - Vol. 119. - P. e1325-1331. http://dx.doi.org/10.1542/peds.2006-0211
- Yang Z., McMahon C., Smith L. et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children // Circulation. - 2005. - Vol. 112. - P. 1612-1617. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.546481